# Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

> **NCT03092674** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 76 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Myelodysplastic Syndrome/Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Cytarabine
- **DRUG:** Decitabine
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Midostaurin
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03092674
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-02
- **Primary completion:** 2023-08-01
- **Final completion:** 2024-06-26
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03092674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03092674, "Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03092674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*